Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01014546
Show Display Options
Rank Status Study
1 Terminated Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Conditions: Essential Thrombocythemia;   Polycythemia Vera;   Primary Myelofibrosis
Interventions: Drug: Arsenic Trioxide;   Dietary Supplement: Ascorbic Acid;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study

Indicates status has not been verified in more than two years